证券研究报告 ➢ siRNA药物机制优势突出，递送为核心技术 相较于传统小分子和生物药，siRNA药物为代表的核酸疗法可精准沉默致病蛋白，高效降解且作用时间长，目前已成为新药开发热门方向。 技术层面主要包括修饰和递送，其中递送为核心技术，肝外递送是目前的突破重心，技术路径包括LNP、抗体、肽类以及VLP递送，各有优劣， 其中AOC发展稍快。 ➢ 海外巨头渐入收获期，静待肝外递送POC 黎明已至，国产争先 ——siRNA药物行业深度报告 行业投资评级：强大于市|维持 盛丽华/陈灿 中邮证券研究所 医药生物团队 中邮证券 1 1 发布时间：2026-02-27 投资要点 siRNA行业先驱Alnylam开发的GalNAc肝内递送凭借递送效率极高、特异性强以及作用持久等优势，已成为肝递送的"标准答案"，其他海 外巨头如Arrowhead和Dicerna等针对PCSK9、AGT、Lp(a)以及ApoC3等心血管常见靶点的siRNA药物已进入临床后期或商业化的收获期，而 针对肌肉、神经系统以及眼部等肝外器官目前仍处于研发早期阶段，目前Alnylam的C16递送平台已在CNS领域、Arrowhead的TRiM平台在脂 肪 ...

iBio Conference Call Summary Company Overview - **Company**: iBio (NYSEAM:IBIO) - **Event**: FY Conference on February 26, 2026 - **Speakers**: Martin Brenner (CEO and CSO), Felipe Duran (CFO) Industry Insights - **Focus Area**: Obesity treatment and related therapies - **Key Drug Class**: GLP-1 (Glucagon-like peptide-1) drugs have shown significant efficacy in obesity treatment, previously achievable only through invasive surgery [3][4] - **Market Need**: There is a growing need for therapies that address the shortcomings of GLP-1 drugs, particularly in preventing lean mass loss and maintaining weight loss [7][9] Core Strategies and Products - **Portfolio Strategy**: iBio is focusing on second-generation drugs that address unmet patient needs beyond GLP-1s, including: - **IBIO-600**: A myostatin molecule aimed at preventing lean mass loss during weight loss [7] - **Activin E**: A long-acting molecule that targets fat-specific weight loss while preserving muscle [14][19] - **Bispecific Molecule**: Targeting myostatin and activin A for conditions like HFpEF (Heart Failure with preserved Ejection Fraction) and obesity [11][30] Clinical Development and Milestones - **Upcoming Data**: Non-human primate data for IBIO-610 expected in the next 30 to 60 days, with presentations planned at ADA ObesityWeek and the European Diabetic Association meeting [10][40] - **IND Filings**: Plans to file for IND equivalent in Australia by the second half of 2026, with first patient dosing anticipated in early 2027 [10][11] - **Clinical Trials**: Emphasis on Phase 1 studies for IBIO-610, leveraging insights from competitors like Arrowhead and Wave [42][44] Market Potential - **Obesity Statistics**: Approximately 1 billion obese individuals worldwide, with a treatable population estimated at 100 to 200 million [19][20] - **Antibody Modality**: iBio's approach to using antibodies for obesity treatment is expected to allow for scalable production and flexibility in market entry [20] Competitive Landscape - **Differentiation**: iBio aims to differentiate its products from existing therapies by focusing on mechanisms that reduce adverse effects associated with GLP-1s and other treatments [8][32] - **Market Position**: The company is positioned as a potential leader in the obesity treatment space, particularly with its unique antibody approaches [52] Financial Overview - **Market Capitalization**: iBio has a market cap of approximately $500 million, with a low float of 34.5 million shares outstanding [36] - **Funding**: The company is well-capitalized, with cash reserves expected to last until the first quarter of 2028, allowing for continued development of its assets [36] Additional Insights - **Patient Journey**: Highlighted the challenges patients face with GLP-1 treatments, including muscle loss and rapid weight regain after discontinuation [5][6] - **Regulatory Considerations**: Acknowledgment of the lack of a regulatory path for weight maintenance drugs, but optimism that high unmet medical needs will drive future decisions [9] Conclusion - iBio is strategically positioned to address significant unmet needs in obesity treatment through innovative drug development and a focus on maintaining muscle mass during weight loss. The upcoming clinical data and regulatory filings will be critical in establishing its market presence and therapeutic efficacy.

While PAH is a rare condition, it represents a sizable commercial opportunity. According to Research and Markets, the global PAH market was valued at $8.29 billion in 2024 and is projected to reach nearly $12 billion by 2030, as demand for novel therapies continues to build.The first Bank of America pick we’re looking at is Inhibikase Therapeutics, a small-cap biotech focused on kinase biology, with its current lead effort aimed at pulmonary arterial hypertension, or PAH. It’s a brutal disease driven by pro ...

Core Viewpoint - Wave Life Sciences Ltd. (NASDAQ:WVE) is identified as a promising investment opportunity with significant upside potential, particularly driven by its obesity medication, WVE-007, which is expected to generate substantial sales and contribute significantly to the company's valuation [1][2]. Group 1: Analyst Ratings and Price Targets - BofA initiated coverage of Wave Life Sciences with a Buy rating and a price target of $38, highlighting WVE-007 as a key value driver, projected to peak at over $11 billion in sales [1]. - Canaccord Genuity raised its price target for Wave Life Sciences to $43 from $40 while maintaining a Buy rating, following the company's announcement of regaining full rights to WVE-006 from GSK [2]. - H.C. Wainwright reiterated a Buy rating with a price target of $30, emphasizing that the return of rights from GSK allows Wave Life to operate independently and focus on smaller, rarer conditions [2]. Group 2: Company Overview - Wave Life Sciences is a clinical-stage biotechnology company that specializes in developing proprietary RNA medicines and has a diverse pipeline targeting various therapeutic areas [3].

Core Viewpoint - Wave Life Sciences (NASDAQ:WVE) is identified as one of the biotechnology stocks with significant upside potential, with a consensus bullish sentiment among analysts and a projected price target indicating over 154% upside [1]. Group 1: Analyst Ratings and Price Targets - As of February 12, all 15 analysts covering Wave Life Sciences have assigned Buy ratings, with a median 1-year price target of $32.57 [1]. - William Maughan from Clear Street reiterated his Buy rating and raised the target price from $47 to $50, suggesting an upside of nearly 291% for investors [2]. Group 2: Company Developments and Pipeline - The transfer of rights to WVE-006 for alpha-1 antitrypsin deficiency from GlaxoSmithKline is viewed positively, although the greater significance lies in WVE-007 for the stock's valuation [3]. - Wave Life Sciences focuses on developing and commercializing RNA medicines, utilizing its PRISM technology platform for precision targeting of diseases [4]. - The company has a pipeline that includes WVE-006, WVE-007, and WVE-N531, indicating a diverse range of therapeutic programs [4].

Summary of siRNA Industry Insights Industry Overview - The siRNA drug market is projected to reach $50.3 billion by 2040, indicating a significant growth opportunity in the nucleic acid therapy sector, which is gaining traction as a new drug development direction [1][1][1] Key Insights - siRNA drugs offer high efficiency, low toxicity, and long-lasting effects compared to traditional small molecules and biologics, making them a popular choice in new drug development [1][1][1] - The GalNAc liver delivery platform has matured, showing high delivery efficiency and specificity, becoming the standard for liver-targeted siRNA drugs. Notable targets include PCSK9, AGT, Lp(a), and ApoC3, which have demonstrated therapeutic potential [1][1][1] - There is potential for breakthroughs in extrahepatic delivery systems, with early-stage developments in areas such as muscle, CNS, and ocular applications. Alnylam's C16 delivery platform is showing promise in Alzheimer's disease, while Arrowhead and Wave Life Sciences are exploring fat tissue targets [1][1][1] Market Dynamics - Domestic siRNA companies are positioned to capitalize on the demand for new technologies as traditional chronic disease drugs approach the end of their sales lifecycle. Collaborations with multinational corporations (MNCs) are expected to increase, particularly in liver delivery systems [2][2][2] - The industry outlook is optimistic, with domestic siRNA drugs likely to secure partnerships in popular targets like PCSK9 and Lp(a). New demands in weight loss and CNS delivery are further opening up the market as international giants make breakthroughs [2][2][2] Relevant Companies - A-share listed companies: Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Bibetech, Sunshine Nuohuo, Chengdu Xian Dao - Hong Kong listed companies: Reebio, and upcoming IPOs such as Jingyin Biotech and Bowe Pharmaceutical - Upstream industry chain participants include WuXi AppTec, Lianhua Technology, Aorite, Lanxiao Technology, Nawei Microbiology, and Jiuzhou Pharmaceutical [2][2][2]

Core Insights - Wave Life Sciences Ltd (NASDAQ:WVE) is recognized as one of the 13 best revenue growth stocks to buy currently [1] - The company regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, from GSK, addressing a significant unmet medical need [1][3] - The disease affects approximately 200,000 individuals in the U.S. and Europe, with no approved therapies available for its lung and liver manifestations [1] Company Strategy - Wave Life Sciences is accelerating its strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration regarding a potential accelerated approval pathway, with regulatory feedback anticipated by mid-2026 [3] - The collaboration with GSK allows Wave Life to be eligible for up to $2.8 billion in various milestones and tiered royalties [3] - The company's cash runway is projected to sustain operations until the third quarter of 2028 [3] Market Position - Analyst Yun Zhong from Wedbush has maintained a Buy rating on Wave Life's stock, setting a price target of $33 [3] - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA-based genetic medicines utilizing its proprietary PRISM platform for stereopure oligonucleotides [3]

Core Insights - The report summarizes significant analyst rating adjustments that could influence market trends, highlighting both upgrades and downgrades across various companies [1]. Upgrades - B. Riley upgraded Snap (SNAP) from Neutral to Buy, maintaining a target price of $10, citing strong growth in high-end subscription revenue and the rollout of high-margin advertising formats [5]. - Seaport Research upgraded FuboTV (FUBO) from Neutral to Buy with a target price of $3, viewing current uncertainties as a quality investment opportunity following a significant stock drop post-earnings [5]. - Wolfe Research upgraded Zoom Video Communications (ZM) from Peer Perform to Outperform, setting a target price of $115, anticipating a re-acceleration in growth and strong performance in its contract center and phone business [5]. - Jefferies upgraded Celanese (CE) from Hold to Buy, raising the target price from $43 to $86, suggesting it is a good time to buy despite potential earnings volatility in the first half of 2026 [5]. - Cantor Fitzgerald upgraded DigitalOcean (DOCN) from Neutral to Overweight, increasing the target price from $47 to $68, emphasizing its focus on digital-native enterprises and a strong foundation for market expansion [5]. Downgrades - Stifel downgraded Microsoft (MSFT) from Buy to Hold, reducing the target price from $540 to $392, citing supply issues with Azure and strong competition from Google Cloud [5]. - Susquehanna downgraded Qualcomm (QCOM) from Positive to Neutral, lowering the target price from $210 to $140, recommending a wait-and-see approach due to industry challenges [5]. - Citigroup downgraded Six Flags Entertainment (FUN) from Buy to Neutral, cutting the target price from $25 to $20, citing overvaluation after a 40% increase since November [5]. - Jefferies downgraded Steven Madden (SHOO) from Hold to Underperform, lowering the target price from $37 to $30, highlighting ongoing pressures in its wholesale business [5]. - JPMorgan downgraded Corteva (CTVA) from Overweight to Neutral, raising the target price from $75 to $77, based on valuation considerations [5]. Initiations - Benchmark initiated coverage on Cava Group (CAVA) with a Buy rating and a target price of $80, recognizing its leading position in the Mediterranean dining category [5]. - H.C. Wainwright initiated coverage on Incyte (INCY) with a Buy rating and a target price of $135, noting potential catalysts that could stabilize revenue expectations post-Jakafi patent expiration [5]. - Bernstein initiated coverage on Coupang (CPNG) with an Underperform rating and a target price of $17, favoring companies with strong growth potential driven by online penetration [5]. - Benchmark initiated coverage on Andersons (ANDE) with a Buy rating and a target price of $75, highlighting the growth momentum in its ethanol business [5]. - Bank of America initiated coverage on Wave Life Sciences (WVE) with a Buy rating and a target price of $38, emphasizing the differentiated advantages of its obesity drug WVE-007 [6].

Core Viewpoint - Clear Street has raised the price target for Wave Life Sciences (WVE) to $50 from $47 while maintaining a Buy rating, viewing the return of rights to WVE-006 by GSK as an overall positive development [1] Group 1: Price Target and Rating - Clear Street increased the price target for WVE to $50 from $47 [1] - The firm maintains a Buy rating on WVE shares [1] Group 2: GSK's Decision and Market Reaction - GSK returned the rights to WVE-006 for alpha1-antitrypsin deficiency, which is seen as a positive by Clear Street [1] - The muted stock reaction is attributed to the greater importance of WVE-007 in Wave Life's overall valuation, overshadowing the alpha-1 antitrypsin deficiency program [1] Group 3: Analyst Confidence - Despite GSK's decision, Clear Street continues to believe in the potential of the alpha-1 antitrypsin deficiency program [1]

Core Thesis - Prestige Consumer Healthcare Inc. (PBH) is viewed as a compelling investment opportunity following its acquisition of Stampede Culinary Partners for $662.5 million, which is expected to enhance its EBITDA significantly [2][3]. Company Overview - PBH develops, manufactures, markets, distributes, and sells over-the-counter health and personal care products in North America, Australia, and internationally [2]. Acquisition Details - The acquisition of Stampede Culinary Partners is structured with $512.5 million in cash, $150 million in stock (approximately 5% dilution), and an additional $100 million earn-out over two fiscal years [2]. - This acquisition is projected to contribute approximately 15% to PBH's EBITDA, with initial mid-single-digit EPS accretion expected to rise to high-single-digit accretion after operational efficiencies are realized, effectively reducing the acquisition multiple to 7.5x [3]. Financial Performance - PBH's earnings run-rate has grown significantly since 2017, although the stock trades near mid-2017 levels. Current-year EPS valuation is around 21x, while next year's estimates reflect a 39% EPS growth, implying a multiple closer to 15x [4]. - The company has a dividend yield above 3% and is positioned for strong growth through strategic acquisitions and organic expansion [5]. Strategic Positioning - PBH's growth strategy has historically combined acquisitions and organic expansion, positioning it as a specialty food producer and distributor in Canada and the U.S. [3]. - Successful integration of Stampede and leveraging operational efficiencies could unlock significant shareholder value while expanding PBH's presence in North America's specialty food sector [5].